 Tacrolimus
"Tacrolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
| Descriptor ID |
D016559
|
| MeSH Number(s) |
D02.540.505.810
|
| Concept/Terms |
Anhydrous Tacrolimus- Anhydrous Tacrolimus
- Tacrolimus, Anhydrous
- Tacrolimus Anhydrous
- Anhydrous, Tacrolimus
|
Below are MeSH descriptors whose meaning is more general than "Tacrolimus".
Below are MeSH descriptors whose meaning is more specific than "Tacrolimus".
This graph shows the total number of publications written about "Tacrolimus" by people in this website by year, and whether "Tacrolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 7 | 0 | 7 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 2 | 0 | 2 | | 2001 | 5 | 2 | 7 | | 2002 | 3 | 2 | 5 | | 2003 | 3 | 4 | 7 | | 2004 | 3 | 3 | 6 | | 2005 | 9 | 4 | 13 | | 2006 | 2 | 0 | 2 | | 2007 | 3 | 2 | 5 | | 2008 | 2 | 1 | 3 | | 2009 | 3 | 1 | 4 | | 2010 | 1 | 2 | 3 | | 2011 | 3 | 2 | 5 | | 2012 | 1 | 1 | 2 | | 2013 | 7 | 2 | 9 | | 2014 | 3 | 1 | 4 | | 2015 | 5 | 0 | 5 | | 2016 | 4 | 1 | 5 | | 2017 | 5 | 0 | 5 | | 2018 | 2 | 1 | 3 | | 2019 | 6 | 1 | 7 | | 2020 | 1 | 2 | 3 | | 2021 | 2 | 5 | 7 | | 2022 | 3 | 2 | 5 | | 2023 | 0 | 2 | 2 | | 2024 | 4 | 1 | 5 | | 2025 | 3 | 1 | 4 | | 2026 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Tacrolimus" by people in Profiles.
-
Thomson D, Dammann A, Benz E, Blanchette E, Bock M, Christofferson ES. Substance Use Patterns in Pediatric Solid Organ Transplant Candidates: Impact After Transplant. Pediatr Transplant. 2026 Aug; 30(8):e70427.
-
Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12; 147(11):1168-1177.
-
Alabi A, Kerr JS, Shah M, Khan A, Ma JD, Suhandynata RT, Momper JD, Tsunoda SM. Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended-Release Tacrolimus (LCPT) Using Grapefruit Juice. Clin Pharmacol Drug Dev. 2026 01; 15(1):e70016.
-
Harris KJR, Ludtke EA, Goldberg B, McCall NN, Hewlett JC, Wilfong EM. Tacrolimus as first-line therapy in a US cohort of idiopathic inflammatory myopathies related interstitial lung disease. Rheumatology (Oxford). 2025 Dec 01; 64(SI):SI179-SI183.
-
Almond CS, Daly KP, Albers EL, Alejos JC, Ameduri R, Auerbach SR, Barkoff L, Barnes AP, Bock MJ, Butto A, Carlo WF, Castleberry CD, Chrisant MR, Deshpande SR, Dreyer WJ, Everitt MD, Feingold B, Gonzales S, Hollander SA, Kindel SJ, Klein GL, Lal AK, Lamour JM, Lee J, Lu M, Lytrivi ID, Miyamoto SD, Pahl E, Peng DM, Ryan TD, Singh TP, Su JA, Sutcliffe DL, Ybarra AM, Zangwill S, Rossano JW, Sleeper LA. Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. JAMA. 2025 Oct 21; 334(15):1339-1348.
-
Klawitter J, Kirkpatrick BE, Shillingburg R, Klawitter J, Wheeler G, Shokati T, Cadnapaphornchai MA, Galinkin JL, Thurman JM, Christians U. Monitoring of Allograft Adaptation After Kidney Transplantation in Pediatric Patients by Targeted Plasma Metabolomics. Int J Mol Sci. 2025 Sep 20; 26(18).
-
Alabi A, Ge M, Momper JD, Tsunoda SM, Kelner MJ, Fitzgerald RL, Suhandynata RT. Measurement of Whole Blood Tacrolimus Concentrations by LC-MS/MS and Immunoassay Methods: Influence of Immediate-Release vs Extended-Release Tacrolimus Formulations. J Appl Lab Med. 2025 May 02; 10(3):546-558.
-
Bae EK, Chandran MM, Everitt MD, Benz E, Bock M. LCP-Tacrolimus Extended-Release (Envarsus XR) Use in Adolescent and Young Adult Solid Organ Transplant Recipients. Clin Transplant. 2024 08; 38(8):e15417.
-
Deininger KM, Anderson HD, Patrinos GP, Mitropoulou C, Aquilante CL. Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data. Pharmacogenomics J. 2024 05 15; 24(3):14.
-
Bader CS, Pavlova A, Lowsky R, Muffly LS, Shiraz P, Arai S, Johnston LJ, Rezvani AR, Weng WK, Miklos DB, Frank MJ, Tamaresis JS, Agrawal V, Bharadwaj S, Sidana S, Shizuru JA, Fernhoff NB, Putnam A, Killian S, Xie BJ, Negrin RS, Meyer EH. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD. Blood Adv. 2024 03 12; 8(5):1105-1115.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|